Navigation Links
YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS
Date:9/23/2007

ear:

- YM USA was cleared by the US FDA to expand its second-line clinical

trial in children with inoperable, recurrent, treatment-resistant

brain cancer into the US

- Oncoscience AG reported completion of patient enrolment in the

Phase III, first-line, pediatric brain cancer trial.

- Oncoscience AG reported initiation of late-stage trials in adult

glioma and pancreatic cancer.

- YM reported positive preliminary results of a Phase I/II trial of

nimotuzumab in combination with radiation for the treatment of

non-small-cell lung cancer (NSCLC).

- The first 20 patients were recruited into the Phase II colorectal

trial by the date of this release.

AeroLEF(TM):

AeroLEF(TM) is a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain. AeroLEF(TM) permits patients to identify and select the appropriate dose in real-time for each pain episode to achieve both rapid onset and extended duration of analgesia.

During Fiscal 2007:

- YM announced that AeroLEF(TM) had met the primary endpoint in its

first randomized, placebo-controlled Phase IIb trial enrolling opioid-

naive patients with post-operative pain following orthopedic surgery.

A statistically significant difference in pain relief and pain

intensity to placebo (p=0.0194) was reported.

- YM received clearance from the FDA to initiate a Phase II trial in the

US in opioid tolerant or opioid-naive patients. A successful trial

would further extend the utility and medical breadth of the product if

and when approved. Enrollment in its 50-patient trial is expected to

start in calendar Q4, 2007.

- A request to the FDA for an End-of-Phase II meeting prior to calendar

year-end 2007 to discuss Phase III trial desi
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014  NeuroLifeSciences ... of mazindol in children with attention deficit/hyperactivity disorder published ... 2014 . The paper, titled "Pilot ... deficit/hyperactivity disorder" ( Konofal et al, Drug ... 2014 ) shows that mazindol might be an ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of autologous ... out of the University of Calgary in conjunction with ... Carolina, which further validates the company,s ongoing clinical research ... effects of pattern baldness. The paper entitled ...
(Date:12/22/2014)... 2014  ( www.competitivehealth.com ) — Competitive Health is ... review and advocacy service, has signed an agreement to ... discount health services marketplace. 63% of Americans ... they expected to pay. As part of an ongoing ... Savings is pleased to offer medical bill review and ...
(Date:12/22/2014)... Fertility Associates of Memphis has announced a new ... network of more than 20 contributing fertility practices ... access to a national pool of frozen donor ... of Memphis is the only fertility clinic in the ... Dr. William Kutteh , director of Fertility Associates of ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3
... Gastrotomy Closure Considered Largest Hurdle in Adoption of Incisionless ... Translumenal Endoscopic Surgery (NOTES), SAN CLEMENTE, Calif., Dec. ... field of Incisionless Surgery, today announced that,its EndoSurgical Operating ... a gastrotomy (an incision in the stomach wall) during,a ...
... Protocol Assessment for Reviroc, AMSTERDAM, December 19 ... completed an End of Phase II meeting for ... Reviroc is under,development for elimination of cancer cells ... end-stage blood cancer patients. The FDA,agreed that the ...
... Inc., (Amex:,ADL), today announced that its subsidiary, Jade ... nutraceutical,diagnostic, consumer healthcare and personal care products, is ... Personal Care Center in Hangzhou,China. The state-of-the-art facility ... flagship JPGreen Health and Personal Care Center., ...
Cached Biology Technology:USGI Medical Demonstrates First System for Gastrotomy Closure in NOTES 2Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc 2AMDL's First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou, China 2
(Date:12/22/2014)... , Dec. 22, 2014 Research ... has announced the addition of the ... report to their offering. ... insight provides an overview of the global ... aims to control and monitor piracy by ...
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research and ... addition of the "Micro Market Monitor: North America ... http://photos.prnewswire.com/prnh/20130307/600769 ... grow at a CAGR of 3.6% from 2014 to ... in this market, Canada is ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 ... than the iPhone 5S, Samsung introduces for the ... The Galaxy S5 home button presents ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... Pittsburgh of UPMC have identified a potential target ... trachomatis, the most prevalent sexually transmitted bacterial infection ... Toni Darville, MD, chief of the Division of ... strain of Chlamydia that, when investigated in an ...
... artificial heart-valve replacements face several repeat operations as they ... and must be traded for bigger ones. Researchers at ... growing valves created in the lab from a patients ... published September 11, they describe making pulmonary valves through ...
... critical to how successful treatment can be. Therefore, the ... field, where every small step is of great importance. ... Cellular Proteomics, Uppsala University researchers describe a technique that the ... bodys cells and tissues, and our knowledge of the human ...
Cached Biology News:Study by Pittsburgh researchers identifies possible vaccine target for chlamydia 2A step toward tissue-engineered heart structures for children 2